OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-03-31-accounts

Charity Registration No. 1166012

Company Registration No. 9816385 (England and Wales)

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2025

BRITISH THORACIC ONCOLOGY GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees Professor D Talbot (Chairman)
Mr C Kerr (Treasurer)
Professor M D Peake
Ms V Beattie (Appointed 26 November 2024)
Professor C Faivre-Finn (Appointed 14 November 2024)
Ms J Fenemore (Appointed 18 November 2024)
Chief Operating Officer Ms D E McKinley
Steering Committee Chair Professor S Popat (to 5 March 2025)
Dr T Newsom-Davis (from 6 March 2025)
Charity number 1166012
Company number 9816385
Principal address 235 Loughborough Road
Mountsorrel
Loughborough
Leicestershire
LE12 7AS
Registered office 235 Loughborough Road
Mountsorrel
Loughborough
Leicestershire
LE12 7AS
Auditor P T Barnett FCCA
Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT
Bankers Santander UK plc
Bridle Road
Bootle
Merseyside
L30 4GB

BRITISH THORACIC ONCOLOGY GROUP

CONTENTS

Page
Trustees' report 1 - 32
Independent auditor's report 33 - 35
Statement of financial activities 36
Balance sheet 37
Statement of cash flows 38
Notes to the financial statements 39 - 48

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 MARCH 2025

The trustees, who are the directors of the charitable company, present their report and financial statements for the year ended 31 March 2025. The BTOG Board of Trustees (“trustees”) are responsible for safeguarding the values and purpose of BTOG and ensuring that activities contribute to achieving the objects of the charity and that BTOG follows its legal obligations.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity’s governing document, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: Statement of Recommended Practice for Charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The legal and administrative information forms part of this report.

OBJECTIVES AND ACTIVITIES

The charitable objects are:

----- Start of picture text -----
The British Thoracic Oncology Group (BTOG) is the
multi-disciplinary group for healthcare
professionals involved with thoracic malignancies
throughout the UK.
----- End of picture text -----

Our Vision

To contribute to achieving survival rates equal to the best in the world.

Our Mission

To support and educate thoracic oncology healthcare professionals, creating a professional community to exchange ideas, information and innovation and to foster the development of research. The overall aim is to represent the needs of people with thoracic malignancies in the UK and ensure they have equitable access to optimal care.

Our Values

Commitment Pride Collaboration
We are committed to achieving We are proud to be an important part We work collaboratively with
our mission and vision. of the thoracic oncology professional other groups who in their own
community. ways are also striving to improve
outcomes for this group of
patients.
Engagement Professionalism Focussed
We engage with our We maintain professional We hold patients at the centre
stakeholders to ensure what independence from commercial of everything we do.
we do is relevant and effective. organisations.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

Strategic Outcomes

01 To reach all lung /mesothelioma MDTs in the UK to ensure all thoracic oncology healthcare professionals have access to relevant education and resources.

02

To be a leader in thoracic oncology research to focus and support the research agenda.

03

To represent thoracic oncology patients by making contributions and collaborating with others.

----- Start of picture text -----
Strategic Activities
Make www.btog.org the one- Develop education and resources for
stop resource shop for thoracic Identify and communicate with lung trainees e.g. trainee E-news and
oncology healthcare and mesothelioma MDTs. forum
professionals
----- End of picture text -----

Education Conference (Flagship Event) Produce standard slide sets in identified areas of interest e.g. Produce standard slide sets in identified areas of interest e.g.
Essential Updates The TNMv9 stage classification for lung cancer
Workshops (ad hoc) Produce Breaking News/Alerts/Press
Annual updates from thoracic oncology international Releases for Changes in Practice
conferences Trainee-specific resources including newsletters, Slack
Produce a podcast series on hot topics and recent data channel, dedicated Annual Conference session
releases
Essential Updates for New Consultants e.g. Oncology or
Respiratory
Research Establish BTOG Special Interest Groups to complement other Develop a Research Strategy to focus and support the thoracic
external subgroups oncology research agenda
Ensure BTOG Special Interest Groups report regularly on the Research Group to advise trainees on research proposals
delivery of specific objectives Promote and support trainee research projects
Representation Make reactive contributions: NICE appraisals; Specialist Partner with specialist societies / groups / organisations (e.g.
Statement of Practice; Endorsements Surgeons, Nurses, Pathologists, Radiologists)
Make proactive contributions: Guidelines; Position and Engage with advocates by ensuring advocate representation
Consensus Statements; Comment on Public Health England / on the BTOG steering committee and making advocate places
Department of Health Policy available at BTOG educational events
Support relevant campaigns for equitable access to optimal Recognise the future Implementation of Screening and ctDNA
care and make proactive contributions by commenting on and the importance of BTOG representation
Public Health England and Department of Health Policy Represent all the UK including the devolved nations

Activities for achieving objectives for the public benefit

The trustees have had regard to the Charity Commission’s guidance on public benefit. The main activities undertaken to further the charitable purposes for the public benefit are set out above.

Criteria to measure success in the reporting period;

We measure our success in achieving our objectives in several of ways by:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

The BTOG Steering Committee

The BTOG Steering Committee (pictured below at BTOG 2025) are from the following specialities:

And they

During this year, the BTOG steering committee saw 4 steering committee members step-down and 3 new steering committee members join representing Surgery, Medical Oncology and Respiratory Medicine specialities. And after 13 years as chair of the BTOG Steering Committee, Professor Sanjay Popat (left) officially handed over the reins to Dr Tom Newsom-Davis (right). In a heartwarming speech at BTOG’s 23rd Annual Conference 2025, Denis Talbot, Chair of BTOG’s Board of Trustees gave thanks for Sanjay’s vision, leadership and impact on the thoracic oncology community.

Tom said: “It is the greatest honour to be appointed Chair of the Steering Committee. I look forward to working with committee colleagues, and the BTOG executive, to continue the fantastic work that BTOG has already done to improve thoracic oncology care in the UK.”

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE

Review of Activities – Education

During the 2024/25 year, BTOG has provided a relevant Continuing Professional Development (CPD) education programme for the thoracic oncology multi-disciplinary team.

The annual conference is BTOG’s flagship event.

It is a 3-day educational event, CPD accredited and involves national and international experts. The programme includes presentations, panel discussions, specialist parallel sessions, poster oral presentations and collaborative sessions. BTOG strives to create an environment at the annual conference that facilitates interaction between colleagues.

Accredited by:

The Federation of the Royal Colleges of Physicians of the United Kingdom

Learning Objectives:

  1. To update all attendees on state-of-the-art management of lung cancer and other thoracic malignancies; to develop new national research studies in lung cancer and mesothelioma

  2. To give knowledge of new procedures for the management of lung cancer and other thoracic malignancies.

  3. To increase understanding of multi-disciplines on the nature of clinical practice and research and to learn from clinical experts about implication on UK practice now and in the future.

  4. 4 -

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Education (continued)

----- Start of picture text -----
BTOG 2024 HIGHLIGHTS
The Lifetime Achievement Award was
presented by Professor Michael Peake
(left) to Professor David Baldwin
(middle)
Professor Charles Swanton (right)
delivered the Keynote Lecture
----- End of picture text -----

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG 2025 HIGHLIGHTS

The Lifetime Achievement Award was presented by Professor Gary Middleton (middle) to Professor Cindy Billingham (left)

Professor Pasi Jänne (right) delivered the Keynote Lecture

After 13 years as chair of the BTOG Steering Committee, Professor Sanjay Popat officially handed over the reins to Dr Tom Newsom-Davis.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Feedback from BTOG 2024 and BTOG 2025 held in Belfast, Northern Ireland

All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias. The main request was for more time for discussion.

Feedback highlights:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

The Mesothelioma Essential Update 2024 was approved for 7 CPD credits from the Federation of the Royal Colleges of Physicians of the United Kingdom (Ref: 149933).

233 delegates attended the Mesothelioma Essential Update 2024 on 9[th] December 2024 at the Cavendish Conference Centre in London and of these 246 were healthcare professionals. Chaired and led by Dr Riyaz Shah, Consultant Medical Oncologist at the Kent Oncology Centre and BTOG Steering Committee Member (pictured below) and Liz Darlison MBE DL, Consultant Nurse at University Hospitals of Leicester NHS Trust and Chief Executive Officer of Mesothelioma UK.

All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias. The main request was for more time for discussion.

Feedback highlights:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

The Therapeutic Strategies for Stage 4 Essential Update 2024 was approved for 6 CPD credits from the Federation of the Royal Colleges of Physicians of the United Kingdom (Ref: 150266).

141 delegates attended the Therapeutic Strategies for Stage 4 Essential on 31[st] January 2025 at the Cavendish Conference Centre in London and of these 89 were healthcare professionals. Chaired and led by Professor Sanjay Popat, Chair BTOG Steering Committee and Consultant Thoracic Medical Oncologist at the Royal Marsden Hospital and Professor of Thoracic Oncology at the Institute of Cancer Research (pictured below).

All participants agreed or strongly agreed with all our feedback questions that checked relevance, learning, structure, effectiveness, organisation, time for discussion and avoided undue commercial bias.

Feedback highlights:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Lung Cancer Sessions brought to you by the Video Journal of Oncology (VJOncology)

At the 23rd BTOG Annual Conference 2025 in Belfast, UK, leading thoracic oncology experts got together to share their highlights and perspectives on molecular testing and clinical decision-making in non-small cell lung cancer (NSCLC). The roundtable discussion on biomarker testing in lung cancer featured BTOG Steering Committee Chair-Elect, Thomas Newsom-Davis (Chelsea and Westminster Hospital NHS Foundation Trust, London, UK) and BTOG Steering Committee member, Alastair Greystoke (Newcastle University/Northern Centre for Cancer Care, Newcastle, UK).

Lung Cancer Sessions: Molecular testing and clinical decision making in NSCLC - VJOncology Part 1: The Role of Genomic Testing in Lung Cancer

Part 2: Understanding Biomarker Testing and Its Practical Application Part 3: Genetic Aberrations and Targeted Therapies in Lung Cancer

Webinars

BTOG continued with its regular short (typically around 1-hour) webinars that were developed when in-person events were not possible. These webinars take account of the latest data released and include a panel of relevant experts in thoracic oncology. Registration at all BTOG webinars is free of charge for health care professionals.

We held three 1-hour webinars during this year, and all events and webinars were accredited by the Federation of the Royal Colleges of Physicians of the UK for category 1 (external) CPD credits. CPD credits were available both live and up to 4 weeks post-event for on-demand and the stats provided below reflect this timeframe. Attendees were encouraged to give feedback on the content and organisation, and any feedback was recorded and analysed to ensure continuous improvement.

Webinars migrated to being hosted directly on btog.org rather than the separate btogwebinars.org site in April 2024; still supported and managed by First Sight Media. Single login simplifies user experience. All BTOG webinars are also available to view ‘On Demand’ in the BTOG Member Only Resources area and to download as a podcast. Video recordings of in-person events are available in the BTOG Member Only Resources within 2 weeks for attendees of the event and 6 months post-event for other members.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Live and on-demand

During this year the webinars released were watched by 250 of this total 225 were health care professionals.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Podcasts of all BTOG webinars are available to listen to or download. BTOG also publishes a series of podcasts called “BTOG does …” where we discuss a variety of thoracic oncology topics with a different expert each time. You can subscribe to BTOG podcasts through the Apple App Store and the Google Play Store or listen on Spotify by searching BTOG (CPD points are not available for the podcasts).

During this year a total of 6,330 podcast downloads, compared to 7,863 in the previous year. 24,700 total downloads since podcasts were started in November 2021.

----- Start of picture text -----
639 downloads
----- End of picture text -----

----- Start of picture text -----
346 downloads
----- End of picture text -----

----- Start of picture text -----
240 downloads
----- End of picture text -----

----- Start of picture text -----
546 downloads
----- End of picture text -----

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Membership

During this year BTOG continued to provide relevant and up-to-date member services.

1[st] E-News April 2024 Last E-News March 2025

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

During this year 4 Trainee E-news were released, produced by the BTOG Steering Committee Trainee representatives. The open rate and click rate are well above the industry average which suggests it is widely read.

----- Start of picture text -----
Open
Issue
Rate Click Rate
Apr 24 74% 4.30%
Aug 24 75% 6.00%
Nov 24 55% 4.88%
----- End of picture text -----

Feb 25 56% 4.25%

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

BTOG Membership Stats

March 2025

Health Care Professionals Members by Speciality

----- Start of picture text -----
Respiratory 23%
Nursing 19%
Medical Oncology 12%
Clinical Oncology 12%
Oncology 5%
Science/research/clinical trials 3%
Surgery 4%
Radiology 3%
Pathology 2%
Allied HCP 3%
Pharmacy 1%
Palliative Care 1%
Academic 0.6%
Student 0.7%
----- End of picture text -----

Health Care Professionals Members by Geography

Based on the sample of 2,101 members with this field completed

----- Start of picture text -----
Yorkshire and the Humber 233
North West 193
East Midlands 325
North West London 136
South London 132
South West 140
West Midlands 142
Scotland 130
East of England 122
Kent, Surrey and Sussex 182
North Central and East London 152
Thames Valley 70
Wales 66
Northern Ireland 36
Republic of Ireland 42
----- End of picture text -----

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

4,059 followers (3,816 last year, 6% increase)

----- Start of picture text -----
New Followers
24-25 23-24 22-23 21-22 20-21 19-20 18-19
NEW 242 396 224 467 479 510 602
INCREASE 6.3% 12% 7% 18% 21% 29% 29%
Mentions
24-25 23-24 22-23 21-22 20-21 19-20 18-19
TOTALS 1,201 1,314 706 1,118 902 926 706
Impressions
24-25 23-24 22-23 21-22 20-21 19-20 18-19
TOTALS 202,598 330,975 154,557 437,459 274,800 283,600 184,400
----- End of picture text -----

3.67% engagement rate (average across healthcare is 0.98%). X is event-driven, with 13,000 post impressions on March 3rd, the first day of the Annual Conference. The April 2024 spike is the Annual Conference, the December spike is the Mesothelioma Essential Update.

Highest Engagement Most Impressions Most Retweets

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

Website – www.btog.org

----- Start of picture text -----
Users Pageviews Avg. session duration Pages per session
18-19 13,818 86,157 02:14 3.29
19-20 19,679 116,303 01:55 3.56
20-21 18,181 82,029 01:35 3.15
21-22 20,648 155,999 01:50 4.56
22-23 20,508 143,117 01:46 4.01
23-24 11,118 63,565 01.56 NA
24-25 14,685 80,700 03.43 2.43
----- End of picture text -----

80% of traffic is from the UK, 8% from the US, 2% India then Ireland, China, Germany, Italy, Spain, Netherlands and France.

Website traffic over time

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities - Education (continued)

53% is desktop and 46% is mobile, an increasing proportion is mobile. Mobile continues to grow in popularity for accessing the website and therefore BTOG will ensure website accessibility for mobile viewers to ensure a good experience for all visitors.

Top Referrers

Traffic Sources

Traffic Sources
Google / organic
Top search terms:BTOG 2024andBTOG		 43%
(direct) / (none) 38%
Social (96% = Twitter) 4%
Other 14%

TOP PAGES

  1. Home

  2. 2025 Annual Conference

  3. 2024 Annual Conference

  4. Mesothelioma Essential Update

  5. Events

  6. Join BTOG

  7. Podcasts

  8. Stage 4 Therapeutic Strategies

  9. Thymic SIG

  10. ASCO 2024 Update

Join BTOG | BTOG | British Thoracic Oncology Group

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research

During this year two Supplements to Lung Cancer were published at BTOG 2024 and BTOG 2025. The supplements showcased important work in 488 abstracts from colleagues in the UK and beyond – research or audit relevant to thoracic oncology including Basic Science, Diagnosis and Staging, Radiotherapy, Screening, Supportive Care, Surgery and more.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

A BTOG Special Interest Group (SIG) is a sub-group of the BTOG steering committee with a shared interest in advancing a specific area of thoracic oncology. Members co-operate to affect change or improvement within that speciality. They may communicate, meet, and organise further training or education and resources for the purpose of advancement. They can use the BTOG logo in relation to the SIG. The aim of the BTOG SIGs is to promote the highest standards of knowledge and facilitate research and representation in that specific area of thoracic oncology.

The BTOG Thymic Malignancies SIG, chaired by Dr David Gilligan. Tumours of the thymus gland constitute a rare but significant part of thoracic oncology. Management of these tumours can be complex and is often poorly understood. The BTOG Thymic Malignancies SIG is a multi-disciplinary group of interested health care professionals, including the patient advocacy group Thymic UK. The aims of this group are to promote understanding, improve knowledge of thymic tumours and to work co-operatively to improve the management pathways for thymic tumours.

During this year the group met 5 times on-line and also in person at the annual meeting in Belfast in April 2024 and March 2025. Highlights of work below:

Continuing workstreams for 2025/2026 include

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

The BTOG Large Cell Neuroendocrine Carcinoma (LCNEC) SIG, chaired by Dr Colin Lindsay, met 5 times during this year. Members will work together to share knowledge and cases to establish a standard of care for Lung LCNECs including but not limited to:

Pathology workflow – The pathology panel has uploaded >20 small biopsy cases, paired with surgically confirmed LCNEC and unconfirmed LCNEC cases, to a central viewing platform. They have now begun blinded anonymous review of these cases using an established Clinical Report Form. The pathology panel convenes every 2-4 weeks to discuss results/problems. In addition, the lead pathologist, Anshuman Chaturvedi, and the new LCNEC Clinical Fellow, Becky Ward, are preparing ~70 historical LCNEC cases for retrospective Rb1 staining and targeted NGS – also due to be uploaded for central review.

Oncology workflow - A protocol has been submitted to REC and CAG for a real-world database study called ‘LCNEC Foundations’, centrally hosted using RedCap, where UK centres will be able to submit collated clinical outcomes of their LCNEC patients. With the support of the BTOG Research Group, the LCNEC Special Interest Group have also submitted phase II trial proposals to both MSD (I-DXd) and Biontech (BNT-327) – aiming to justify a first national LCNEC clinical trial.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

The BTOG Research Group , chaired by Professor Sanjay Popat, met 7 times during this year. It is an invited group of health care professionals recognised for their leadership in clinical trials and research aiming to develop and foster clinical research in thoracic oncology, to take over some of the functions of the defunct NCRI Lung CSG.

The purpose of the BTOG Research Group is to:

During this year the BTOG Research Group has:

Governance

Studies

Grant calls

Meetings

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Research (continued)

To support research and represent thoracic oncology patients by making contributions and collaborating with others.

BTOG circulated various surveys during this year to BTOG members via BTOG E-news:

May 2024 - Sheffield Hallam University – survey related to a study "Exploring Oncologists' and Health Care Professionals' Perspectives: Physical Activity in Advanced Cancer Care". Results from this study will be used in conjunction with further patient scoping work in the design and implementation of a patient and health care led PA intervention in patients with advanced cancer. August 2024 - LCNEC BTOG Special Interest Group – survey to ascertain the current understanding of the standard of care of large cell neuroendocrine carcinoma patients from UK-based centres.

September 2024, Colleagues at Guy's and St Thomas' – survey on real-world attitudes of clinicians towards neoadjuvant and peri-operative chemo immunotherapy in resectable lung cancer.

October and November 2024 - International Thymic Malignancy Interest Group (ITMIG) – survey to look at daily practice to identify areas of agreement and potential controversy in the current global clinical and pathology practice of the diagnosis and treatment of thymic epithelial tumors.

November and December 2024 - Thymic Malignancies BTOG Special Interest Group – survey to ask for feedback on the thymic lesion diagnostic algorithm published earlier in this year.

December 2024 - Professor Matthew Evison and Professor Kevin Blyth – survey for input to map the use of important ancillary diagnostic tests in mesothelioma (BAP-1 and MTAP/P16 FISH) across the UK.

March 2025 - LCNUK – survey to inform the production and implementation of a Navigator Framework to provide clear and consistent guidance on the Navigator role within the Lung Cancer setting.

March 2025 - University of Birmingham – survey which aims to improve understanding of what happens when patients are diagnosed with pulmonary nodules. Speaking to patients, doctors, and administrative staff, they hope to understand the process patients go through and whether this process can be improved to reduce the likelihood of nodules being followed up improperly.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation

February 2025 - BTOG supported a grant application submitted to Roy Castle Lung Cancer Foundation related to a study looking at improving access and recruitment to clinical trials for cancer patients submitted by Professor Catherine Henshall, Clinical Academic Nurse.

March 2025 – BTOG joined other organisations including British Thoracic Society and Mesothelioma UK in writing to the Secretary of State for Health and Social Care to request intervention to establish a National Mesothelioma Clinical Audit. This is crucial to improving treatment standards, ensuring equitable access to care, and reducing the economic burden of this preventable disease.

Advocates

BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma. BTOG ensures that …

Collaboration

BTOG works collaboratively with many organisations, societies, and groups, to build close and enduring relationships and to have mutual memberships to ensure representation. Steering Committee members undertake this work on behalf of BTOG and these include the following examples:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)

NICE Representation

NICE appraisals review and make recommendations on the clinical and cost-effectiveness of medicines and treatments in the NHS.

During this period BTOG provided expertise and representation on 57 NICE Scoping and Full Appraisals to improve access to treatment for patients affected by thoracic malignancies. There were 30 negative/suspended trials not included in the above total.

Participating in a NICE appraisal involves a significant time and effort commitment by the representatives involved including:

During this period 8 NICE appraisals resulted in positive recommendations for treatment options.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

ACHIEVEMENTS AND PERFORMANCE (CONTINUED)

Review of Activities – Representation (continued)

NICE Representation (continued)

Ref Appraisal

Source: https://x.com/NICEComms

6293 Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

Review of Activities – Representation (continued)

NICE Representation (continued)

Ref Appraisal Source: https://x.com/NICEComms 6368 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer

6404 Durvalumab in combination with platinum-based chemotherapy for untreated extensive stage small-cell lung cancer

BTOG Steering Committee Representatives involved in NICE appraisals

Jason Adhikaree 2 Tom Newsom-Davis 5
Samreen Ahmed 6 (1 joint) Sanjay Popat 11
Shobhit Baijal 6 Riyaz Shah 2
AlastairGreystoke 3 James Spicer 4
Adam Januszewski 1 Yvonne Summers 2 (1 joint)

Co-opted non-Steering Committee Representatives involved in NICE appraisals

Sanjay Agrawal 3 Matthew Krebbs 1
Martin Forster 1 Mary O’Brien 1
Matthew Hatton 1 Robin Young 1

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

FINANCIAL REVIEW

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that BTOG has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

Finance Overview

Our Annual Conferences over the last few years were held in January 2022, April 2023, April 2024 and March 2025, therefore no annual conferences were held in financial year ending 2023, one was held in financial year ending 2024 and two in the financial year ending 2025. This has had a large impact in both income for sponsorship and registration fees. Total income for the year increased from £764,573 in 2024 to £1,696,222 in 2025.

Total expenditure for the year ended 31 March 2025 increased this year amounting to £1,524,010 (2024 - £779,727). The expenditure was split between charitable activities costs in the sum of £1,470,452 and costs of raising funds in the sum of £53,558.

Net income (expenditure) for the year ended 31 March 2025 amounted to £172,212 compared to £(15,154) in the previous year.

----- Start of picture text -----
Income Expenditure
3%
36%
64%
97%
Charitable activities Other trading Charitable activities Raising funds
----- End of picture text -----

Risk Management

A risk policy and a detailed risk register have been produced. The risk register covers governance, external, financial, operational and regulatory risk and a review of the risk register is a standing item at every trustee meeting. The trustees are satisfied that systems and procedures are in place to mitigate exposure to the major risks. A major risk to BTOG is the reliance on registration fees and external sponsorship income to provide enough funding for BTOG to deliver its aims and objectives. This is particularly relevant given the COVID-19 pandemic. Mitigating actions include strategic planning, operating a reserves policy and ongoing engagement with our key sponsors.

Reserves Policy

BTOG is committed to demonstrate good stewardship and active financial management and to identifying through risk assessment and budgeting any uncertainty in future income streams. A major risk to BTOG is the reliance on registration fees and external sponsorship to provide enough funding for BTOG to deliver its aims and objectives. Therefore, the trustees have agreed that at any one time the charity can hold a maximum of 2 years’ normal operating expenditure in reserve. Over recent years the charity has never reached this level of reserves and the trustees have acknowledged that this needs to be discussed and reviewed. Normal operating expenditure is identified in annual budgets which are approved by the trustees. This reserve level will ensure that the current service provided by BTOG is secure in times when income to the charity may be reduced.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

FINANCIAL REVIEW (CONTINUED)

Reserves Policy (continued)

Total reserves as at 31 March 2025 amounted to £717,889 of which £nil are restricted. As at 31 March 2025 free reserves (total unrestricted reserves less unrestricted tangible fixed assets) amounted to £717,389 which is significantly below the trustees’ long term target level of reserves. At current levels of normal activity, the maximum level of reserves would be in the range of £1.5m and £2m.

The trustees are considering measures to try and build up free reserves going forward and they will monitor the level of reserves as part of BTOG’s financial processes. If reserves were to exceed the agreed level (2 years’ normal operating expenditure) BTOG will take immediate steps to reduce the level of those reserves either by increasing expenditure on charitable activities or by reducing its income (or a combination of both). The time frame for this reduction will be within 2 years of discovery of the excess and during that time the trustees will consider whether some or all the reserves can be invested to obtain a financial return for the charity.

STRUCTURE GOVERNANCE AND MANAGEMENT

Constitution

British Thoracic Oncology Group registered as a company (9816385) on 8[th] October 2015 and as a charity (1166012) on 11[th] March 2016. The company is limited by guarantee and has no share capital. Every member of the company undertakes to contribute to the assets of the company, in the event of winding up, such an amount as may be required not exceeding £1. The governing document is the Memorandum of Association.

Trustees

The following trustees have served since 1 April 2024:

Professor D Talbot (Chairman from 7-Oct-24) Mr AM Grange (Chairman until resigned 7-Oct-24) Mr Christopher Kerr (Treasurer) Ms Vanessa Beattie (appointed 26-Nov-24) Mr G Bland (resigned 5-Jul-24) Professor Corinne Faivre-Finn (appointed 14-Nov-24) Ms Jacqueline Fenemore (appointed 18-Nov-24) Professor Michael D Peake

BTOG welcomed 3 new trustees during this period.

Method of Appointment or Election of Trustees

The management of the charity is the responsibility of the trustees elected under the Memorandum of Association of BTOG. Trustees set the policies for the recruitment, induction and training of new trustees. In selecting individuals for appointment as new trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity. Upon appointment, trustees are provided with an induction pack which includes various items such as the governing document, the latest financial statements, policy documents and Charity Commission guidance.

Pay Policy for Staff

During this reporting period BTOG did not employ its own staff. From 1st April 2025 the post of Chief Operating Officer was employed directly by BTOG. An NHS Trust employed the staff and charged the associated salary costs to the charity in accordance with a service level agreement. Pay levels for posts supported by the charity but employed by the NHS Trust are determined through standard NHS procedures.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making

The trustees are responsible for BTOG; they safeguard the values and purpose of BTOG and check activities contribute to achieving the objects and ensure BTOG follows its legal obligations. Trustees are Non-Executive Directors of BTOG. The trustees during this reporting period comprised an emeritus consultant and honorary professor of respiratory medicine/specialist clinical advisor for Cancer Research UK; two lung cancer specialist nurses, a professor and consultant clinical oncologist, a retired professor/medical oncologist; a retired tax inspector, a retired lawyer and a retired senior pharmaceutical professional. The trustees and Steering Committee Chair decide the policies which provide the framework for the work of BTOG; decide overall aims and objectives, priorities and strategy; monitor and evaluate progress and delegate day-to-day work to the BTOG Chief Operating Officer (COO) and other appointed staff/agents. The trustees meet 4 times/year and communicate by email at all other times. One trustee also attends Steering Committee meetings as an observer (subject to availability).

The Steering Committee Chair is an Executive Officer of BTOG, accountable to the trustees. The Steering Committee supports BTOG’s aims and objectives; take an active role in the delivery of the BTOG educational programme; comments and advises on thoracic oncology guidelines for care or treatment; represents BTOG on other thoracic oncology boards/committees/groups and recognises their affiliation to BTOG in their work. The Steering Committee are Executive Officers of BTOG, accountable to the SC Chair. The Steering Committee meet in person 4 times/year and communicate by email at all other times. The Steering Committee members represent the thoracic oncology multi-disciplinary team. In addition, BTOG recognises the importance of input from advocates in improving outcomes for lung cancer and mesothelioma patients and therefore the Steering Committee includes two advocate members. BTOG defines advocates as those who sit on clinical studies or trial management groups, advisory boards/groups or other related groups related to lung cancer or mesothelioma.

BTOG is a member of the National Council for Voluntary Organisations (NCVO) and trustees have access to online resources and information for charities. The trustees are required to update their trustee knowledge and training regularly to ensure they understand their role and responsibilities. Trustees periodically attend both theoretical and practical training courses organised by the NCVO covering a wide variety of charitable issues and they also complete online training.

The COO carries out the work of BTOG; reports regularly on achievements and progress; makes decisions (where the power to do this has been delegated); provides information on issues, problems and policy matters and makes recommendations; draws up plans for the future development of BTOG’s work for the Trustees and Steering Committee to decide upon; advises and informs the trustee board so that it is able to carry out its governing role and recruits and appoints staff/agents. The COO is reportable to University Hospitals of Leicester NHS Trust (UHL) Line Manager and Steering Committee Chair and accountable to the trustees.

The relationship of the BTOG Executive is based on a shared vision for BTOG; a commitment to achieving the objectives of BTOG; clear and understood trustee roles to not interfere inappropriately with the day-to-day running of BTOG; confidence in the abilities of the COO and willingness to back the judgement of the COO in the event of problems (providing they have been kept informed); the provision of good information to enable informed decisions to be made and a clear management framework and lines of accountability.

The COO and Executive Officer (EO) are paid roles employed by UHL, who charge the associated salary costs to the charity in accordance with a formal service level agreement. Communications/website, conference and accountancy services were contracted out to external commercial providers. All other roles in the BTOG Executive are unpaid.

Following the pandemic, starting 1[st] February 2022, BTOG have leased an office from Mesothelioma UK in Mountsorrel, Leicester and there is a Memorandum of Understanding in place in this respect. BTOG staff do a combination of office and home working.

BTOG works collaboratively with many organisations including Mesothelioma UK (a related party) in the pursuit of its charitable activities.

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STRUCTURE GOVERNANCE AND MANAGEMENT (CONTINUED)

Organisational Structure and Decision Making (continued)

BTOG recognised the need for appropriate governance to ensure transparent working and therefore has a comprehensive portfolio of policies covering charity structure, roles and responsibilities of trustees and the steering committee, conflict of interest, finance, procurement, reserves, endorsement, media and privacy, developed taking account of Charity Commission guidance. The policies are reviewed as per the review dates and new policies are developed as needed/identified and are available in the Governance section of the BTOG website.

The Trustees confirm that the major risks relating to BTOG have been reviewed and systems and procedures have been established to manage those risks, as detailed on page 19 under risk management.

Plans for Future Years

BTOG will continue to work towards its strategic outcomes, mission and vision as per pages 1 and 2.

During the 2025/26 year and beyond we plan to:

Education

Research

Representation

Governance and Operational

STATEMENT OF TRUSTEES’ RESPONSIBILITES

The trustees (who are also directors of BTOG for the purposes of company law) are responsible for preparing the Trustees’ Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure of the charitable company for that period. In preparing these financial statements, the trustees are required to:

BRITISH THORACIC ONCOLOGY GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2025

STATEMENT OF TRUSTEES’ RESPONSIBILITES (CONTINUED)

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

The trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report has been prepared in accordance with the special provisions relating to small companies within Part 15 of the Companies Act 2006.

Approved by the Board of Trustees on 16 December 2025 and signed on its behalf by:

Professor D Talbot

Chair of the Board of Trustees

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

Opinion

We have audited the financial statements of British Thoracic Oncology Group (the ‘charitable company’) for the year ended 31 March 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company’s ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Trustee's Report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the Trustee's Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

Responsibilities of trustees

As explained more fully in the statement of trustees' responsibilities set out on pages 31-32, the trustees (who are also the directors of the charitable company for the purpose of company law), are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that Act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities

We identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and then design and perform audit procedures responsive to those risks, including obtaining audit evidence that is sufficient and appropriate to provide a basis for our opinion. However, responsibility for the prevention and detection of fraud ultimately rests with both those charged with governance and management of the charitable company.

In identifying and assessing risks of material misstatement in respect of irregularities, including fraud and noncompliance with laws and regulations, our procedures included the following:

BRITISH THORACIC ONCOLOGY GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF BRITISH THORACIC ONCOLOGY GROUP

Audit response to risks of irregularities identified

Our procedures to respond to risks identified included the following:

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https:// www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Other matters

In the previous accounting period, the directors of the company took advantage of audit exemption under section 477 of the Companies Act 2006. Therefore, the comparative financial statements are unaudited.

Use of our report

This report is made solely to the charity’s trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity’s trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

18 December 2025

Chartered Accountants Statutory Auditor West Walk Building 110 Regent Road Leicester LE1 7LT

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT FOR THE YEAR ENDED 31 MARCH 2025

Unrestricted Unrestricted
Funds Funds
Total Total
2025 2024
Notes £ £
Income from:
Charitable activities 3 602,272 281,073
Other trading activities 4 1,093,950 483,500
Total 1,696,222 764,573
Expenditure on:
Raising funds 5 53,558 39,274
Charitable activities 6 1,470,452 740,453
Total 1,524,010 779,727
Net income/(expenditure) for the year/
Net movement in funds 172,212 (15,154)
Reconciliation of funds
Total funds brought forward 545,677 560,831
Total funds carried forward 717,889 545,677

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

BRITISH THORACIC ONCOLOGY GROUP

BALANCE SHEET

AS AT 31 MARCH 2025

Notes
Fixed assets
Tangible assets
11
Current assets
Debtors
12
Cash at bank and in hand
Liabilities
Creditors: amounts falling due within one
year
13
Net current assets
Net assets
Total funds of the charity
Designated funds
General funds
Total unrestricted funds
15
Total charity funds		 2025
£
£
500
243,220
547,903
791,123
(73,734)
717,389
717,889
5,831
712,058
717,889
717,889		 2024
£
£
1,020
445,838
622,660
1,068,498
(523,841)
544,657
545,677
17,775
527,902
545,677
545,677		 2024
£
£
1,020
445,838
622,660
1,068,498
(523,841)
544,657
545,677
17,775
527,902
545,677
545,677
545,677
545,677
545,677

The company is entitled to the exemption from the audit requirement contained in section 477 of the Companies Act 2006, for the year ended 31 March 2025, although an audit has been carried out under section 144 of the Charities Act 2011.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

Trustees' responsibilities:

The financial statements were approved and authorised for issue by the Board of Trustees on 16 December 2025 and are signed on its behalf by:

Mr C Kerr Trustee and Treasurer

Company Registration No. 9816385

BRITISH THORACIC ONCOLOGY GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 MARCH 2025

Notes
Cash flows from operating activities
Cash (absorbed by)/generated from
operations
20
Investing activities
Purchase of tangible fixed assets
Net cash used in investing activities
Net cash used in financing activities
Net (decrease)/increase in cash and cash
equivalents
Cash and cash equivalents at beginning of year
Cash and cash equivalents at end of year		 2025
£
-		 £
(74,757)
-
-
(74,757)
622,660
547,903		 2024
£
(1,316)		 £
231,820
(1,316)
-
230,504
392,156
622,660

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

Charity information

British Thoracic Oncology Group ("BTOG") is a private company limited by guarantee incorporated in England and Wales. The address of the registered office and place of business is given in the legal and administrative information page of these financial statements.

The members of the charity include the trustees named within the legal and administrative information. In the event of the trust being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

1.1 Basis of preparation

The charitable company is a Public Benefit Entity as defined by FRS 102. The financial statements have been prepared in accordance with: the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

The financial statements are prepared in sterling, which is the functional currency of the charitable company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charitable company has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Designated funds are unrestricted funds of the charity which have been set aside at the discretion of the trustees for specific purposes. The purposes and uses of the designated funds are set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charitable company is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Income from charitable activities primarily includes income received for conference and course registration fees. Such income is recognised at fair value when the event has occurred.

Income from trading activities includes income earned from sponsorship.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.5 Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is legal or constructive obligation to make the payment to a third party, if it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

Irrecoverable VAT is charged against the category of resources expensed for which it was incurred.

Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs and governance costs. They are incurred directly in support of expenditure on the objects of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 8.

1.6 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

Fixtures & fittings 15% of cost Computer equipment 33.33% of cost

1.7 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less.

1.8 Financial instruments

Financial instruments are recognised in the charitable company's balance sheet when the charitable company becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.9 Taxation

British Thoracic Oncology Group is a registered charity and no taxation provision is required as its income from charitable activities falls within the various exemptions available to registered charities.

1.10 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

1 Accounting policies

(Continued)

1.11 Leases

Rentals payable under operating leases, including any lease incentives received, are charged to the SOFA on a straight line basis over the term of the relevant lease.

2 Critical accounting estimates and judgements

In the application of the charitable company’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimation uncertainty that have a significant effect on the amounts recognised in the financial statements.

3 Charitable activities

Unrestricted
Restricted
funds
funds
£
£
Conference and course registration fees
602,272
-
Unrestricted funds
Restricted funds
Conference and course registration fees breakdown:
BTOG 2025
BTOG 2024
BTOG 2023
Essential Update Therapeutic Strategies for Stage 4
Mesothelioma Essential Update 2024
Essential Update 2023		 Total
2025
£
602,272
2025
£
329,461
262,910
-
6,200
3,701
-
602,272		 Total
2024
£
281,073
281,073
-
281,073
2024
£
-
-
280,423
-
-
650
281,073

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

4 Other trading activities

Unrestricted
Restricted
funds
funds
2025
2025
£
£
Sponsorship
1,093,950
-
Unrestricted funds
Restricted funds		 Total
2025
£
1,093,950		 Total
2024
£
483,500
483,500
-
483,500

5 Raising funds

Unrestricted
Restricted
funds
funds
£
£
Advertising, marketing, direct mail and publicity
31,169
-
Support costs (see note 8)
22,389
-
53,558
-
Unrestricted funds
Restricted funds		 Total
2025
£
31,169
22,389
53,558		 Total
2024
£
18,569
20,705
39,274
39,274
-
39,274

6 Charitable activities

Activities
undertaken
directly
Note 7
£
Conference and courses
1,292,413
Unrestricted funds
Restricted funds		 Support
Costs
Note 8
£
178,039		 Total
2025
£
1,470,452
1,470,452
-
1,470,452		 Total
2024
£
740,453
740,453
-
740,453

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

7 Expenditure on activities undertaken directly

Conference and courses
Venue and accommodation management
Abstract publication
Prizes and bursaries
Travel
Course accreditation
Bank and card charges
Webinar activities
Venue and acommodation management breakdown:
BTOG 2025
BTOG 2024
BTOG 2023
Essential Update Therapeutic Strategies for Stage 4
Mesothelioma Essential Update 2024
Essential update 2023
New Consultants Study Day
Other		 2025
£
1,189,835
42,213
3,050
33,612
1,292
15,551
6,860
1,292,413
2025
£
604,566
554,204
-
12,220
18,845
-
-
-
1,189,835		 2024
£
546,642
16,754
1,650
39,208
795
8,472
5,022
618,543
2024
£
-
-
514,097
-
-
25,370
4,791
2,384
546,642

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

8 Expenditure on support costs

Basis of allocation
Staff costs
Raising funds and
charitable activities
Travel
Charitable activities
Training
Charitable activities
Subscriptions
Charitable activities
Rent
Charitable activities
Insurance
Charitable activities
Office costs
Charitable activities
Software costs
Charitable activities
Professional fees
Charitable activities
Sundry
Charitable activities
Irrecoverable VAT
Charitable activities
Depreciation
Charitable activities
Analysed between:
Raising funds
Charitable activities		 2025
£
111,944
24
176
254
4,260
13,608
980
2,125
12,689
-
53,848
520
200,428
22,389
178,039
200,428		 2024
£
103,529
150
160
489
4,260
6,814
1,108
2,729
6,173
32
16,627
544
142,615
20,705
121,910
142,615

Support costs have been allocated to raising funds and charitable activities on a basis consistent with the use of the resource. Support costs include governance costs totalling £10,949 (2024: £6,173).

The amount charged to the SOFA in respect of governance costs includes the following: Statutory audit £9,010 (2024: independent examination £4,775) Other financial services £1,939 (2024: £1,398)

9 Trustees

The trustees neither received nor waived any emoluments during the year (2024: £Nil).

Travel and subsistence expenses were reimbursed to 1 trustees (2024: 1) in the sum of £24 (2024: £150) during the year.

10 Employees

The average monthly number of employees during the year was:

2025 2024
Number Number
Total 2 2

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

10 Employees (Continued)
Employment costs 2025 2024
£ £
Wages and salaries 111,944 103,529

Staff working for the charity are employed directly by the University Hospitals of Leicester NHS Trust and their salary costs are charged to the charity in accordance with a service level agreement between BTOG and the Trust. The amount charged for the year was £111,944 (2024 - £103,529).

There were no employees whose annual remuneration was more than £60,000.

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

2025 2024
£ £
Aggregate compensation 66,435 62,942

11 Tangible fixed assets

Fixtures &
fittings
Computer
equipment
£
£
Cost
At 1 April 2024
692
1,821
At 31 March 2025
692
1,821
Depreciation and impairment
At 1 April 2024
549
944
Depreciation charged in the year
81
439
At 31 March 2025
630
1,383
Carrying amount
At 31 March 2025
62
438
At 31 March 2024
143
877		 Total
£
2,513
2,513
1,493
520
2,013
500
1,020

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

12
Debtors
Amounts falling due within one year:
Trade debtors
Other debtors
Prepayments and accrued income		 2025
£
88,180
5,832
149,208
243,220		 2024
£
283,267
17,776
144,795
445,838
13
Creditors: amounts falling due within one year
Other taxation and social security
Deferred income (see note 14)
Other creditors
Accruals
14
Deferred income
Arising from advanced registration fees and
sponsorships
Deferred income is included in the financial statements as follows:
Deferred income is included within:
Current liabilities
Movements in the year:
Deferred income at 1 April 2024
Released from previous periods

Resources deferred in the year
Deferred income at 31 March 2025		 2025
£
63,967
-
-
9,767
73,734
2025
£
-		 2024
£
64,335
447,075
5,400
7,031
523,841
2024
£
447,075
2025
2024
£
£
-
447,075
447,075
510,467
(447,075)
(510,467)
-
447,075
-
447,075		 2024
£
447,075
447,075

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

15 Unrestricted funds

The unrestricted funds of the charity include designated funds which have been set aside out of unrestricted funds by the trustees for a specific purpose:

Balance at
1 April 2024
£
General funds
527,902
Designated funds - wages fund
17,775
545,677
Balance at
1 April 2023
£
General funds
559,527
Designated funds - wages fund
1,304
560,831		 Movement in funds
Income
Expenditure
£
£
1,696,222
(1,412,066)
-
(111,944)
1,696,222
(1,524,010)
Movement in funds
Income
Expenditure
£
£
764,573
(676,198)
-
(103,529)
764,573
(779,727)		 Transfers
Balance at
31 March 2025
£
£
(100,000)
712,058
100,000
5,831
-
717,889
Transfers
Balance at
31 March 2024
£
£
(120,000)
527,902
120,000
17,775
-
545,677		 Transfers
Balance at
31 March 2025
£
£
(100,000)
712,058
100,000
5,831
-
717,889
Transfers
Balance at
31 March 2024
£
£
(120,000)
527,902
120,000
17,775
-
545,677
£
764,573
-
764,573
545,677

The wages fund represents funds held by the University Hospitals of Leicester NHS Trust as Custodian Trustee on behalf of British Thoracic Oncology Group for primarily the payment of wages to staff working for the charity but who are employed by the NHS Trust.

16 Analysis of net assets between funds

Analysis of net assets between funds
Unrestricted
Designated
funds
funds
£
£
Fund balances at 31 March 2025 are represented by:
Tangible assets
500
-
Current assets/(liabilities)
711,558
5,831
712,058
5,831
Unrestricted
Designated
funds
funds
£
£
Fund balances at 31 March 2024 are represented by:
Tangible assets
1,020
-
Current assets/(liabilities)
526,882
17,775
527,902
17,775		 Total
£
500
717,389
717,889
Total
£
1,020
544,657
545,677

BRITISH THORACIC ONCOLOGY GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 MARCH 2025

17 Related party transactions

During the year rent and office expenses in the sum of £4,260 (2024 - £4,260) were invoiced by Mesothelioma UK Charitable Incorporated Organisation (formerly Mesothelioma UK Charitable Trust) to the British Thoracic Oncology Group, to which Ms D E McKinley was a trustee of this organisation until 31-Dec-24. At the balance sheet date there was an outstanding balance of £nil (2024 - £nil) for these services.

There have been no further related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 9 to the financial statements.

18 Operating lease commitments

At 31 March 2024 the charity had outstanding commitments for future minimum lease payments under noncancellable operating leases, which fall due as follows:

2025 2024
£ £
Within one year 3,550 3,550

Lease payments totalling £4,260 (2024 - £4,260) have been recognised as an expense during the year.

19 Controlling party

British Thoracic Oncology Group is a company limited by guarantee and not having a share capital; it is incorporated under the Companies Act and governed by the Memorandum and Articles of Association of the charity. The trustees of the charity are elected members and act as directors of the charity who are deemed to be the controlling party of the charity.

20
Cash generated from operations
2025
£
Surplus/(deficit) for the year
172,212
Adjustments for:
Depreciation and impairment of tangible fixed assets
520
Movements in working capital:
Decrease in debtors
202,618
(Decrease)/increase in creditors
(3,032)
(Decrease) in deferred income
(447,075)
Cash (absorbed by)/generated from operations
(74,757)		 2024
£
(15,154)
544
305,966
3,856
(63,392)
231,820